Barclays’s Regenxbio RGNX Stock Holding History

Barclays’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Hold	26,800	–	–	﹤0.01%	3617
2025 Q4	$386K	Buy	26,800 +5,400	+25%	+$67.3K	﹤0.01%	3995
2025 Q3	$207K	Hold	21,400	–	–	﹤0.01%	4274
2025 Q2	$176K	Hold	21,400	–	–	﹤0.01%	4360
2025 Q1	$153K	Buy	+21,400	New	+$159K	﹤0.01%	4192
2024 Q2	–	Sell	-25,000	Closed	-$527K	–	5229
2024 Q1	$527K	Buy	+25,000	New	+$445K	﹤0.01%	3555

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's RGNX Position: Q1 2026 in Review

Barclays reduced its Regenxbio (RGNX) stake by 59% in Q1 2026, selling an estimated $1.02M and leaving 67,427 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Barclays first reported a position in RGNX in Q4 2015 and has held it in 40 quarters since. The position peaked at $7.65M in Q4 2019. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Barclays held 67,427 shares of Regenxbio worth $565K as of Q1 2026.
Barclays sold 96,994 Regenxbio shares in Q1 2026, an estimated $1.02M.
Regenxbio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3120 holding.
Barclays first reported a position in Regenxbio in Q4 2015 and has held it in 40 quarters since.
Barclays's Regenxbio position peaked at $7.65M in Q4 2019.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.